Drug development for CNS disorders: strategies for balancing risk and reducing attrition

Menelas N. Pangalos; Lee E. Schechter; Orest Hurko

doi:10.1038/nrd2094

journal article Jul 01, 2007

Drug development for CNS disorders: strategies for balancing risk and reducing attrition

Menelas N. Pangalos Lee E. Schechter Orest Hurko

Nature Reviews Drug Discovery Vol. 6 No. 7 pp. 521-532 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/nrd2094

Topics

No keywords indexed for this article. Browse by subject →

References

129

[1]

Pharmaceutical Research and Manufacturers of America (PhRMA). New Medicines in Development for Mental Illness. PhRMA web site [online] , (2006).

[2]

Pharmaceutical Research and Manufacturers of America (PhRMA). New Medicines in Development for Neurological Disorders. PhRMA web site [online] , (2006).

[3]

Ferri, C. P. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112–2117 (2005). 10.1016/s0140-6736(05)67889-0

[4]

Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004). 10.1038/nrd1470

[5]

Tufts Center for the Study of Drug Development. Longer clinical times are extending time to market for new drugs in US. Tufts CSDD Impact Report 7, 1–4 (2005).

[6]

Bornstein, N., Silvestrelli, G., Caso, V. & Parnetti, L. Arterial hypertension and stroke prevention: an update. Clin. Exp. Hypertens. 28, 317–326 (2006). 10.1080/10641960600549405

[7]

Sato, A., Saruta, T. & Funder J. W. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens. Res. 29, 211–216 (2006). 10.1291/hypres.29.211

[8]

Nitsch, R. M., Slack, B. E., Wurtman, R. J. & Growdon, J. H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304–307 (1992). 10.1126/science.1411529

[9]

Pangalos, M. N., Jacobsen, S. J. & Reinhart, P. H. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the β-amyloid peptide. Biochem. Soc. Trans. 33, 553–558 (2005). 10.1042/bst0330553

[10]

Dominguez, D. I. & De Strooper, B. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. Trends Pharmacol. Sci. 23, 324–330 (2002). 10.1016/s0165-6147(02)02038-2

[11]

Zhang, L. et al. Characterization of the reconstituted γ-secretase complex from Sf9 cells co-expressing presenilin 1, nicastrin, aph-1a, and pen-2. Biochemistry 44, 4450–4457 (2005). 10.1021/bi0481500

[12]

Marambaud, P. et al. A presenilin-1/γ-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J. 21, 1948–1956 (2002). 10.1093/emboj/21.8.1948

[13]

Roberds, S. L. et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317–1324 (2001). 10.1093/hmg/10.12.1317

[14]

Hong, L. et al. Crystal structure of memapsin 2 (β-secretase) in complex with an inhibitor OM00–3. Biochemistry 41, 10963–10967 (2002). 10.1021/bi026232n

[15]

Booth, B. & Zemmel, R. Prospects for productivity. Nature Rev. Drug Discov. 3, 451–456 (2004). 10.1038/nrd1384

[16]

Hornig, C. R. et al. CT contrast enhancement on brain scans and blood–CSF barrier disturbances in cerebral ischemic infarction. Stroke 16, 268–273 (1985). 10.1161/01.str.16.2.268

[17]

Papadopoulos, C. M. et al. Dendritic plasticity in the adult rat following middle cerebral artery occlusion and Nogo-a neutralization. Cereb. Cortex 16, 529–536 (2006). 10.1093/cercor/bhi132

[18]

Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999). 10.1038/22124

[19]

Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916–919 (2000). 10.1038/78682

[20]

Neuropathological stageing of Alzheimer-related changes

H. Braak, E. Braak

Acta Neuropathologica 1991 10.1007/bf00308809

[21]

Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383–421 (2000). 10.1016/s0197-4580(00)00124-x

[22]

Are mitochondria critical in the pathogenesis of Alzheimer's disease?

P. Hemachandra Reddy, M. Flint Beal

Brain Research Reviews 2005 10.1016/j.brainresrev.2005.03.004

[23]

Kivipelto, M. et al. Apolipoprotein E ɛ4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137, 149–155 (2002). 10.7326/0003-4819-137-3-200208060-00006

[24]

Brunton, V. G. et al. Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res. 65, 1335–1342 (2005). 10.1158/0008-5472.can-04-1949

[25]

Paul, R. et al. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nature Med. 7, 222–227 (2001). 10.1038/84675

[26]

Lebovitz, H. Diabetes: assessing the pipeline. Atheroscler. Suppl. 7, 43–49 (2006). 10.1016/j.atherosclerosissup.2006.01.007

[27]

Feinstein, D. L. et al. Peroxisome proliferator-activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51, 694–702 (2002). 10.1002/ana.10206

[28]

Heneka, M. T., Landreth, G. E. & Feinstein, D. L. Role for peroxisome proliferator-activated receptor-γ in Alzheimer's disease. Ann. Neurol. 49, 276 (2001). 10.1002/1531-8249(20010201)49:2<276::aid-ana53>3.0.co;2-5

[29]

Rosenzweig-Lipson, S. et al. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res. 1073–1074, 240–251 (2006). 10.1016/j.brainres.2005.12.052

[30]

Schechter, L. et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2, 590–611 (2005). 10.1602/neurorx.2.4.590

[31]

Porter R. H. et al. A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 315, 711–721 (2005). 10.1124/jpet.105.089839

[32]

Miyamoto, S., Duncan, G. E., Marx, C. E. & Lieberman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79–104 (2005). 10.1038/sj.mp.4001556

[33]

Braff, D. L. L., G. A. . The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin. Neurosci. 7, 125–135 (2005). 10.31887/dcns.2005.7.2/dlbraff

[34]

Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 2752–2758 (1999). 10.1161/01.str.30.12.2752

[35]

Lees, K. R. et al. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 354, 588–600 (2006). 10.1056/nejmoa052980

[36]

Ireland, R. Is NXY-059 beneficial in ischemic stroke? Nature Clin. Pract. Cardiovasc. Med. 3, 240–241 (2006). 10.1038/ncpneuro0167x

[37]

Fong, J. J. & Rhoney, D. H. NXY-059: review of neuroprotective potential for acute stroke. Ann. Pharmacother. 40, 461–471 (2006). 10.1345/aph.1e636

[38]

[No Authors Listed]. The Bitterest pill. Nature 444, 532–533 (2006). 10.1038/444532a

[39]

Leow, A. D. et al. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage 31, 627–640 (2006). 10.1016/j.neuroimage.2005.12.013

[40]

Schenk, D., Games, K. D. & McConlogue, L. The potential utility of transgenic mice harboring β-amyloid precursor protein. Neurobiol. Aging 16, 711–713 (1995). 10.1016/0197-4580(95)00081-o

[41]

Bloom, F. E. et al. Mouse models of human neurodegenerative disorders: requirements for medication development. Arch. Neurol. 62, 185–187 (2005). 10.1001/archneur.62.2.185

[42]

Harrison, S. M. et al. BACE1 (β-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol. Cell. Neurosci. 24, 646–55 (2003). 10.1016/s1044-7431(03)00227-6

[43]

Laird, F. M. et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25, 11693–11709 (2005). 10.1523/jneurosci.2766-05.2005

[44]

Roher, A. E. & Kokjohn, T. A. Appraisal of AβPP transgenic mice as models for Alzheimer's disease amyloid cascade. Curr. Med. Chem. 3, 85–90 (2003).

[45]

Lehmann, H. E. & Ban, T. A. The history of the psychopharmacology of schizophrenia. Can. J. Psychiatry 42, 152–162 (1997). 10.1177/070674379704200205

[46]

Janssen, P. A., Niemegeers, C. J. & Schellekens, K. H. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data?I. 'Neuroleptic Activity Spectra' for rats. Arzneimittelforschung. 15, 104–117 (1965).

[47]

Costall, B., Naylor, R. J. & Nohria, V. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur. J. Pharmacol. 50, 39–50 (1978). 10.1016/0014-2999(78)90251-0

[48]

Braff, D. L. & Geyer, M. A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 47, 181–188 (1990). 10.1001/archpsyc.1990.01810140081011

[49]

Lipska, B. & Weinberger, D. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23, 223–239 (2000). 10.1016/s0893-133x(00)00137-8

[50]

Cryan, J., Markou, A. & Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23, 238–245 (2002). 10.1016/s0165-6147(02)02017-5

Showing 50 of 129 references

Cited By

289

Pyridine alkaloids with activity in the central nervous system

Simon X. Lin, Maurice A. Curtis · 2020

Bioorganic & Medicinal Chemistr...

Metrics

289

Citations

129

References

Details

Published: Jul 01, 2007
Vol/Issue: 6(7)
Pages: 521-532
License: View

Authors

Cite This Article

Menelas N. Pangalos, Lee E. Schechter, Orest Hurko (2007). Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nature Reviews Drug Discovery, 6(7), 521-532. https://doi.org/10.1038/nrd2094

Drug development for CNS disorders: strategies for balancing risk and reducing attrition

You May Also Like